Last reviewed · How we verify
RP-3500
At a glance
| Generic name | RP-3500 |
|---|---|
| Also known as | Camonsertib |
| Sponsor | Canadian Cancer Trials Group |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma (PHASE1)
- Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer (PHASE2)
- Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors (PHASE1)
- RP-6306 in Patients With Advanced Cancer (PHASE2)
- A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer (PHASE1, PHASE2)
- Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors (PHASE1, PHASE2)
- Study of RP-3500, Camonsertib, in Advanced Solid Tumors (PHASE1, PHASE2)
- RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RP-3500 CI brief — competitive landscape report
- RP-3500 updates RSS · CI watch RSS
- Canadian Cancer Trials Group portfolio CI